17308-02-0

Basic information

• Product Name: 3,20-Dioxopregn-4-en-17-beta-yl acetate
• Synonyms: 17-HYDROXYPROGESTERONE ACETATE;17-ALPHA-HYDROXYPROGESTERONE 17-ACETATE;17ALPHA-HYDROXYPROGESTERONE ACETATE;17ALPHA-HYDROXY-4-PREGNENE-3,20-DIONE 17-ACETATE;17ALPHA-ACETOXYPROGESTERONE;17-ACETOXYPROGESTERONE;17ALPHA-ACETOXY-4-PREGNENE-3,20-DIONE;ACETIC ACID (8R,9S,10R,13S,14S,17R)-17-ACETYL-10,13-DIMETHYL-3-OXO-2,3,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL ESTER
• CAS NO: 17308-02-0
• Molecular Formula: C₂₃H₃₂O₄
• Molecular Weight: 372.5
• EINECS: 206-119-6
• Mol File: 17308-02-0.mol
• Article Data: 11

Chemical Properties

• Melting Point: 198 °C
• Boiling Point: 490.2 °C at 760 mmHg
• Flash Point: 211.576 °C
• Appearance: /
• Density: 1.15 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.543
• CAS DataBase Reference: 3,20-Dioxopregn-4-en-17-beta-yl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 3,20-Dioxopregn-4-en-17-beta-yl acetate(17308-02-0)
• EPA Substance Registry System: 3,20-Dioxopregn-4-en-17-beta-yl acetate(17308-02-0)

Safety Data

• Hazard Codes: Xn
• Statements: 40-48
• Safety Statements: 22-24/25-45
• RIDADR: UN 2811 6.1/PG 2
• WGK Germany: 3
• RTECS: TU5074000
• Hazardous Substances Data: 17308-02-0(Hazardous Substances Data)

Usage

General Description

3,20-Dioxopregn-4-en-17-beta-yl acetate, also known as Prednisolone Acetate, is a synthetic glucocorticoid drug. It is used mainly in the treatment of a wide range of inflammatory and autoimmune conditions such as asthma, uveitis, pyoderma gangrenosum, rheumatoid arthritis, ulcerative colitis, temporal arteritis and Crohn's disease, Bell's palsy, multiple sclerosis, cluster headaches, and autoimmune hepatitis. The compound works by modifying the body's immune response to different conditions, thereby reducing inflammation, swelling, and allergic-type reactions. Its use may be associated with side effects including mood changes, increased risk of infection, and bone thinning.

InChI:InChI=1/C23H32O4/c1-14(24)23(27-15(2)25)12-9-20-18-6-5-16-13-17(26)7-10-21(16,3)19(18)8-11-22(20,23)4/h13,18-20H,5-12H2,1-4H3/t18-,19+,20+,21+,22+,23+/m1/s1

Upstream product

• 64-17-5 ethanol 
• 434-03-7 levonorgestrel 
• 1600-27-7 mercury(II) diacetate 
• 108-24-7 acetic anhydride 
• 109-63-7 trifluoroborane diethyl ether 
• 64-19-7 acetic acid 
• 1250-99-3 3β.17-diacetoxy-17βH-pregnen-(5)-yne-(20) 
• 40264-22-0 21-bromo-17-acetoxy-17βH-pregnene-(4)-dione-(3.20) 
• 127-09-3 sodium acetate 
• 1176-21-2 3β,17-diacetoxy-17βH-pregn-5-en-20-one 
• 2542-26-9 (8R,9S,10R,13S,14S,17R)-17-ethynyl-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate 
• 141-78-6 ethyl acetate 
• 17308-01-9 21.21-dibromo-17-acetoxy-17βH-pregnene-(4)-dione-(3.20) 
• 65851-76-5 17α-ethynyl-17β-nitro-oxy-4-androsten-3-one 

Downstream Products

• 4954-07-8 pregna-3,5-dien-20-one, 3,17-dihydroxy-, diacetate 
• 32634-95-0 17α-Acetoxy-6-methylene-pregn-4-ene-3,20-dione 
• 595-33-5 Megestrol acetate 
• 1054-64-4 17α-acetoxy-3-methoxypregna-3,5-dien-20-one 
• 1616932-89-8 17α-p-iodophenylcarbamoiloxypregn-4,6-dien-3,20-dione 
• 1616932-88-7 17α-p-bromophenylcarbamoiloxypregn-4,6-dien-3,20-dione 
• 1616932-87-6 17α-p-chlorophenylcarbamoiloxypregn-4,6-dien-3,20-dione 
• 1616932-86-5 17α-p-fluorophenylcarbamoiloxypregn-4,6-dien-3,20-dione 
• 1616932-85-4 17α-phenylcarbamoiloxypregn-4,6-dien-3,20-dione 
• 1616932-84-3 17α-p-iodobenzoiloxy-4,6-pregnadien-3,20-dione 
• 1190878-48-8 17α-p-bromobenzoyloxy-4,6-pregnadiene-3,20-dione 
• 1190878-47-7 17α-p-chlorobenzoyloxy-4,6-pregnadiene-3,20-dione 
• 1190878-46-6 17α-p-fluorobenzoyloxy-4,6-pregnadiene-3,20-dione 
• 81480-72-0 17α-benzoyloxy-4,6-pregnadiene-3,20-dione 

Relevant articles and documents

-

-

Preparation process of 17a-hydroxyprogesterone acetate

The invention discloses a preparation process of 17a-hydroxyprogesterone acetate. According to the invention, high-purity 17a-hydroxyprogesterone acetate is obtained sequentially through an acylation reaction, a hydrolysis reaction, a neutralization reaction, centrifugation and refining. Therefore, a process procedure is shortened, raw material input is reduced, and cost is saved.

Microwave induced selective enolization of steroidal ketones and efficient acetylation of sterols in semisolid state

Under microwave irradiation steroidal enones, more specifically, position three carbonyls were efficiently and selectively converted to the corresponding enol acetates in the presence of additional enolizable carbonyl functions at other positions, using acetic anhydride and a catalytic amount of toluene-p-sulfonic acid. Acetylation of hydroxyl groups of the sterols, including those at the hindered positions, was near quantitative. Strictly anhydrous conditions were not a pre-requisite for acetylation and the reaction system easily tolerated up to 10% (v/v) moisture.

Anti-glaucomatous pharmaceutical composition and the process for obtaining them

The invention relates to the domain of medicinal chemistry. It concerns more particularly that of the preparation of pharmaceutical compositions for ocular use. A subject of the invention is pharmaceutical compositions for ocular use characterized in that they contain at least one selected compound of steroidal structure in combination with or admixed with a pharmaceutically-acceptable, inert carrier or vehicle. The compositions according to the invention are intended to the treatment of glaucoma.